1. 630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models. (9th November 2020) Authors: Kantak, Seema; Glaser, Bryan; Wetter, Justin; Sim, Bee-Cheng; Higaki, Jeff; Beal, Jacob; Ollerman, Sara; Pulukkunat, Dileep; Bawadekar, Mandar; Kaplan, Charles; Lamb, Peter; Hammer, Bonnie Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models. (9th November 2020) Authors: Kantak, Seema; Glaser, Bryan; Wetter, Justin; Sim, Bee-Cheng; Higaki, Jeff; Beal, Jacob; Ollerman, Sara; Pulukkunat, Dileep; Bawadekar, Mandar; Kaplan, Charles; Lamb, Peter; Hammer, Bonnie Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗